How and when do you incorporate PTEN testing in a patient newly diagnosed with metastatic hormone-sensitive prostate cancer?
Community PollStarted
How do you incorporate PTEN protein testing in a patient newly diagnosed with mHSPC?
38 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Duke University Hospital
Answered on
Based on the FDA approval of ADT/Abiraterone and Capivasertib for patients with PTEN-deficient metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS) I recommend testing with an FDA-approved immunohistochemistry (IHC) test on the archival tumor tissue of patients with metastatic pr...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · The University of Texas Health Science Center at San Antonio
Answered on
I always incorporate PTEN testing in all patients with mHSPC (mAPMS) using NGS testing. Recently, with the approval of capivasertib, I have also started doing PTEN IHC testing. The NGS information is prognostic in how I educate the patient as well as understand their disease. It also comes as part o...
Join for free or sign in to see the full answer